ConductScience.org, home

Library / Genes

PCSK9: proprotein convertase subtilisin/kexin type 9

1 protein, 346 patents, 11 drugs, 189 trials, 4,687 NIH grants and 13,851 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolPCSK9HGNC
Nameproprotein convertase subtilisin/kexin type 9HGNC
NCBI Gene ID255738NCBI Gene
HGNC IDHGNC:20001HGNC
EnsemblENSG00000169174NCBI Gene
AliasesFH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1, PC9NCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
Q8NBP7Proprotein convertase subtilisin/kexin type 969265Ensembl, GeneID, HGNCUniProt

Patents 346

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
WO 2026141238 A2026-07-027Q8NBP7Espacenet
JP 2026515163 A2026-05-144Q8NBP7Espacenet
JP 2026513776 A2026-05-011823Q8NBP7Espacenet
JP 2026067851 A2026-04-21412Q8NBP7Espacenet
US 12606638 B22026-04-21198Q8NBP7Espacenet
US 12594349 B22026-04-071823Q8NBP7Espacenet
EP 4705273 A22026-03-11576Q8NBP7Espacenet
US 12551573 B22026-02-171823Q8NBP7Espacenet
JP 2026012737 A2026-01-27756Q8NBP7Espacenet
JP 2026004359 A2026-01-1435Q8NBP7Espacenet

Drugs 11

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ALIROCUMABCHEMBL2109540Subtilisin/kexin type 9 inhibitorINHIBITORChEMBL
BOCOCIZUMABCHEMBL3137349Subtilisin/kexin type 9 inhibitorINHIBITORChEMBL
EVOLOCUMABCHEMBL2364655Subtilisin/kexin type 9 inhibitorINHIBITORChEMBL
FROVOCIMABCHEMBL4298016Subtilisin/kexin type 9 inhibitorINHIBITORChEMBL
INCLISIRANCHEMBL3990033PCSK9 mRNA RNAi inhibitorRNAI INHIBITORChEMBL
INCLISIRAN SODIUMCHEMBL5095052PCSK9 mRNA rnai inhibitorRNAI INHIBITORChEMBL
LERODALCIBEPCHEMBL4650405Subtilisin/kexin type 9 inhibitorINHIBITORChEMBL
ONGERICIMABCHEMBL4594566Subtilisin/kexin type 9 inhibitorINHIBITORChEMBL
RALPANCIZUMABCHEMBL3137352Subtilisin/kexin type 9 inhibitorINHIBITORChEMBL
RG-7652CHEMBL2109539Subtilisin/kexin type 9 inhibitorINHIBITORChEMBL

Trials 189

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07477704ALIROCUMABPHASE2ClinicalTrials.gov
NCT07473960TAFOLECIMABPHASE3ClinicalTrials.gov
NCT07388420EVOLOCUMABClinicalTrials.gov
NCT07375225ALIROCUMABClinicalTrials.gov
NCT07341958TAFOLECIMABClinicalTrials.gov
NCT07106034ONGERICIMABPHASE2ClinicalTrials.gov
NCT07102628INCLISIRANPHASE3ClinicalTrials.gov
NCT07061535TAFOLECIMABPHASE2ClinicalTrials.gov
NCT07014215TAFOLECIMABPHASE2ClinicalTrials.gov
NCT06700720EVOLOCUMABPHASE2ClinicalTrials.gov

NIH grants 4687

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30DK063491Diabetes Research Center (DRC)362,025NIH's project files
UL1TR001863Yale Clinical and Translational Science Award232,025NIH's project files
R01HL142711Whole genome sequences in ethnically diverse individuals to comprehensively characterize the genetic mechanisms of dyslipidemias212,025NIH's project files
P30DK020541NYR-Diabetes Research Center (NYR-DRC)202,025NIH's project files
R01HL092577IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVAL192,025NIH's project files
U01HG006379EHR-based Genomic Discovery and Implementation [Funded Extension]192,025NIH's project files
UL1TR001881UCLA Clinical and Translational Science Institute172,025NIH's project files
T32HL007208Integrated, Multidisciplinary Training in Cardiovascular Research152,025NIH's project files
P30DK017047Diabetes Research Center122,025NIH's project files
P30DK020572Michigan Diabetes Research Center (MDRC)122,025NIH's project files

Papers 13851

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42824094PubTator, text miningPubMed
42823400PubTator, text miningPubMed
42811994PubTator, text miningPubMed
42809906PubTator, text miningPubMed
42806111PubTator, text miningPubMed
42805150PubTator, text miningPubMed
42803952PubTator, text miningPubMed
42803385PubTator, text miningPubMed
42799026PubTator, text miningPubMed
42798836PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license